A New Blood Score for Myelofibrosis Staging (FIBROMOELLE)

Assistance Publique - Hôpitaux de Paris

Status: Not yet enrolling

Conditions: Myeloproliferative Neoplasm

Treatments: Diagnostic Test: Blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT06177366

APHP231007

Details and patient eligibility

About

BCR:ABL1 negative myeloproliferative neoplasms (MPN) include three entities: polycythemia vera, essential thrombocythemia and primitive myelofibrosis. Myelofibrosis is a life-threatening complication in MPN with several therapeutic options including hematopoietic stem cell transplantation (HSCT) which remains the only curative treatment. Bone marrow biopsy with histological analysis allows myelofibrosis identification and staging. However, it is an invasive procedure that remains painful and provides potential haemorrhagic complications. Development of non-invasive biomarkers for myelofibrosis staging could help to better stratify this disease, better define patients' prognosis and lead to optimal cares.

The main aim of this work is to develop a non-invasive blood score including several biomarkers for myelofibrosis staging in MPN using bone marrow biopsy as a gold standard.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years
• Diagnosis of BCR::ABL1 negative MPN according to WHO criteria classification
• Indication for bone marrow biopsy
• Non opposition
• Social security affiliation

Exclusion criteria

• Non-contributory biopsy
• AML transformation
• Organ fibrosis (liver, lung, kidney...)
• HSCT
• Chronic inflammatory disease

Trial design

120 participants in 1 patient group

Adults with MPN who need a bone marrow biopsy during the management of the disease

Treatment:

Diagnostic Test: Blood sampling